In regulated industries — pharmaceutical manufacturing, medical device production, clinical laboratories, and life science research — “we believe our product works” is not good enough. Procurement managers, quality assurance officers, and infection-control teams demand independent, reproducible, third-party evidence. That is exactly why DaXem GmbH had VireXbuster® tested by two leading independent laboratories: Fraunhofer IZI for virus deactivation and QualityLabs for antibacterial performance.
This article explains what those tests mean, why they matter, and what the results tell you about choosing a surface hygiene solution you can trust.
What Is Independent Laboratory Testing — And Why Does It Matter?
Any manufacturer can claim their product “kills 99.9% of germs.” What separates a credible claim from marketing noise is the quality of the evidence behind it. Independent third-party testing means a laboratory with no commercial interest in the outcome applies a standardised protocol, measures results under controlled conditions, and issues a formal test report. That report is auditable, reproducible, and defensible in front of a regulatory body or a demanding customer.
For surface coatings and disinfectants used in life sciences environments, independent validation is often a prerequisite for product approval, facility certification, or inclusion on a preferred-supplier list. Fraunhofer IZI and QualityLabs are exactly the kind of institutions whose reports carry that weight.
Fraunhofer IZI: The Gold Standard for Virus Deactivation Testing
The Fraunhofer Institute for Cell Therapy and Immunology (IZI), based in Leipzig, Germany, is one of Europe’s most respected applied research institutions in the life sciences. Its Department of Infection Research and Diagnostics specialises in the development and evaluation of technologies targeting pathogens — including viruses.
Fraunhofer IZI conducts virus deactivation studies using internationally recognised test protocols. When a surface coating undergoes testing at Fraunhofer IZI, researchers apply the product to defined surfaces under standardised conditions and then challenge those surfaces with live viral suspensions. The reduction in viable viral particles is measured and quantified. The result is not an estimate — it is a measured, reproducible scientific finding.
VireXbuster® was tested at Fraunhofer IZI for its ability to deactivate viruses on treated surfaces. This matters particularly for environments where viral contamination poses a genuine risk: hospital waiting rooms, cleanrooms, shared office surfaces, HVAC systems, and public transport interiors. The Fraunhofer IZI test report gives customers in these sectors documented confidence that VireXbuster® performs as described — against real viruses, under real test conditions.
“Fraunhofer IZI virus deactivation testing is not a certification tick-box — it is scientific evidence generated by one of Germany’s most rigorous public research institutions.”
QualityLabs: Independent Antibacterial Efficacy Testing
Bacteria are a different challenge from viruses — different cell structures, different resistance mechanisms, different test protocols. QualityLabs conducted independent antibacterial testing on VireXbuster®, evaluating the product’s efficacy against bacterial strains relevant to surface hygiene and infection prevention.
Antibacterial testing typically measures the reduction of colony-forming units (CFU) on treated surfaces compared to untreated controls. A meaningful result requires statistically significant reduction under standardised conditions — not selective reporting or cherry-picked strains. QualityLabs’ independent status ensures the results are objective and the methodology is transparent.
For life science facilities where bacterial contamination can compromise experiments, products, or patient safety, having documented antibacterial efficacy data is not optional — it is part of the risk management framework. VireXbuster®’s QualityLabs test result supports that framework directly.
The Combined Picture: Viruses AND Bacteria, Independently Confirmed
Most surface hygiene products are tested for one category of pathogen. VireXbuster® has been tested for both — viruses by Fraunhofer IZI and bacteria by QualityLabs. This dual-laboratory validation gives quality and procurement teams a complete picture of antimicrobial performance backed by independent science.
In addition to bacteria and viruses, VireXbuster® is formulated to be effective against fungi and mould, including airborne mould — a critical concern for HVAC systems in hospitals, laboratories, and pharmaceutical clean corridors.
What This Means for Your Facility
If you are evaluating surface hygiene solutions for a regulated or high-hygiene environment, here is what the dual-lab validation of VireXbuster® means in practice:
- Audit readiness: Independent test reports from Fraunhofer IZI and QualityLabs can be submitted as documented evidence in quality audits and facility inspections.
- Procurement confidence: Your quality assurance team can approve VireXbuster® on the basis of external, reproducible scientific data — not manufacturer self-reporting.
- Broad-spectrum coverage: One coating product with documented efficacy against viruses, bacteria, and fungi reduces the complexity and cost of your hygiene programme.
- Long-lasting protection: Unlike spray disinfectants that require repeated application, VireXbuster® is a long-lasting antimicrobial surface coating — meaning the tested protection stays active between cleaning intervals.
Ready to Learn More?
VireXbuster® is available for commercial and institutional applications across Germany and Europe. Whether you manage a pharmaceutical production facility, a medical device cleanroom, a hospital ward, or a large commercial building, our team can advise on application scope, dosage, and documentation for your compliance needs.
Contact DaXem GmbH at info@daxem.de or visit virexbuster.de to request the test documentation or a consultation.
